Abstract

The introduction of emtricitabine/tenofovir diphosphate (FTC/TDF) as pre-exposure prophylaxis (PrEP) for HIV prevention has raised questions regarding which clinicians will serve as prescribers and how providers will be educated about this HIV prevention strategy. We piloted an HIV Prevention Education Program called PrEP University (PrEP U) to address knowledge gaps in HIV prevention among medical trainees. We examined PrEP awareness and assessed learning as a result of the program, measuring knowledge before and after the lectures with an anonymous 5-question multiple choice test. A total of 198 learners participated in PrEP University, which included 127 first year medical students, and post-graduate trainees in internal medicine (n = 23), family medicine (n = 16), OBGYN (n = 13) and pharmacy (n = 19). Prior to PrEP U, 27% of all participants were not aware of PrEP and an additional 8% were unsure if they had heard of it. Knowledge increased significantly after the education program among trainees in OBGYN (2.3 vs 3.8, p < 0.001), pharmacy (1.4 vs 2.5, p = 0.012) and school of medicine (3.3 vs 4.4, p < 0.001), with a trend seen in family medicine (2.7 vs. 3.7, p = 0.067) and internal medicine (2.7 vs 3.4, p = 0.068). Overall, an HIV Prevention Education Program was successfully administered to nearly 200 participants and resulted in improved knowledge of HIV prevention and PrEP across. Pharmacists and OBGYN physicians are two groups with an expanding role in the use of PrEP. Similar programs at other medical schools should be implemented to ensure that future physicians and pharmacists are comfortable with PrEP prescription.

Highlights

  • While much progress has been made in the prevention and treatment of HIV/AIDS, there are still roughly 40,000 new HIV cases each year in the United States (US) [1]

  • A total of 198 learners participated in pre-exposure prophylaxis (PrEP) University, which included 127 first year medical students, 23 Internal Medicine (IM) trainees, 16 Family Medicine (FM) trainees, 13 Obstetrics and Gynecology (OBGYN) trainees, and 19 Pharmacy trainees

  • Forty-seven percent of medical students, 38% of OBGYN trainees, and 17% of IM trainees were not aware of or unsure if they had heard of PrEP as opposed to all of those surveyed in FM and Pharmacy who were aware of PrEP prior to completing the lecture series

Read more

Summary

Introduction

While much progress has been made in the prevention and treatment of HIV/AIDS, there are still roughly 40,000 new HIV cases each year in the United States (US) [1]. In 2012, the Food and Drug Administration (FDA) licensed pre-exposure prophylaxis (PrEP), revolutionizing HIV/AIDS prevention and cultivating a renewed enthusiasm to end the pandemic by 2030 as outlined by the Joint United Nations Programme on HIV and AIDS [2]. This once daily tablet containing a combination of anti-retrovirals emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) or emtricitabine and tenofovir alafenamide (FTC/TAF) has proven to be highly effective as evidenced by multiple clinical trials [3,4,5].

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call